Menu Back toTOPIC-2-SESSION-5-Expedited-Reporting-Requirements-in-the-Post-authorisation-Phase-and-Case-Studies

Joint MHRA/DIA Excellence in Pharmacovigilance

This course is designed to provide a firm grounding in key aspects of European Clinical Pre- and Post-Marketing Safety regulatory requirements.


TOPIC 2 SESSION 5: Expedited Reporting Requirements in the Post-authorisation Phase and Case Studies

Session Chair(s)

Gaby L. Danan, MD, PhD

Gaby L. Danan, MD, PhD

  • Pharmacovigilance Expert
  • GLD, France
Phil  Tregunno

Phil Tregunno

  • Head of Vigilance Operations, Safety & Surveillance
  • Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Speaker(s)

Gaby L. Danan, MD, PhD

Expedited Reporting Requirements in the Post-authorisation Phase and Case Studies

Gaby L. Danan, MD, PhD

  • Pharmacovigilance Expert
  • GLD, France

Contact us


Registration Questions

Send Email
+41 61 225 51 51



Agenda and Logistics

Send Email
+41 61 225 51 55